Engineered immune cells take on Hard-to-Treat cancers

NCT ID NCT05164666

Terminated Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This early-phase trial tests a new cell therapy called TAK-103 in people with advanced or metastatic solid tumors that have a specific marker (mesothelin). Participants have their white blood cells collected, modified in a lab with TAK-103, and then infused back. The study's main goals are to find a safe dose and watch for side effects. Each person receives just one dose and is followed for up to 3 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAK-103 (a cell therapy made from the patient's own white blood cells)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that express mesothelin.
What could go wrong: This is a very early, small Phase 1 trial with only 2 participants. The main goal is safety, not effectiveness. Side effects like cytokine release syndrome or nerve problems may occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Show contact details

Locations

Hyogo College of Medicine Hospital

Nishinomiya, Hyōgo, Japan
National Cancer Center Hospital

Chuo-ku, Tokyo, Japan
National Cancer Center Hospital East

Kashiwa, Chiba, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.